Evidence map›Paper›PMID 18661493›Full record

ArticleAmerican journal of hematology2008

Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura.

Lingli Dong, Visalam Chandrasekaran, Wenhua Zhou, Han-Mou Tsai

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases.Mediterranean journal of hematology and infectious diseases · 2013
    Review
  3. Pathophysiology of thrombotic thrombocytopenic purpura.International journal of hematology · 2010
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lingli DongUnified Division of Hematology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York 10467, USA.
Visalam Chandrasekaran
Wenhua Zhou
Han-Mou Tsai

Funding

VWF PROTEINASE DEFICIENCY IN TTP WITH OR WITHOUT HIVR01HL062136 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI TSAI, HAN-MOU · 1999 to 2008
$2.4M
NHLBI NIH HHS R01 HL062136NHLBI NIH HHS R01 HL62136
6 · The paper itself

Abstract

In a patient with fatal thrombotic thrombocytopenic purpura, the inhibitory activity of antibodies against ADAMTS13 rapidly escalated to extremely high levels despite daily plasma exchange and corticosteroid therapy. This increase was found to be because of a combination of higher antibody concentration and potency. Furthermore, during her course of the disease, the percentage of IgG(1) antibody progressively decreased whereas that of IgG(2) antibody increased, suggesting Th1-type cytokine response. These changes suggest that the course of TTP may be exacerbated by complex immune reactions. Further characterization of the factors contributing to this exacerbation may have important pathogenetic and therapeutic implications.

Indexed as

ADAM ProteinsADAMTS13 ProteinAdolescentAdrenal Cortex HormonesAutoantibodiesEnzyme InhibitorsFatal OutcomeFemaleHumansImmunoglobulin GPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecombinant ProteinsADAM ProteinsADAMTS13 ProteinADAMTS13 protein, humanAdrenal Cortex HormonesAutoantibodiesEnzyme InhibitorsImmunoglobulin GRecombinant Proteins

Identifiers

PMID18661493
PMCPMC2574606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.